BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 22355408)

  • 21. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
    Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T
    Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aβ38 in the brains of patients with sporadic and familial Alzheimer's disease and transgenic mouse models.
    Reinert J; Martens H; Huettenrauch M; Kolbow T; Lannfelt L; Ingelsson M; Paetau A; Verkkoniemi-Ahola A; Bayer TA; Wirths O
    J Alzheimers Dis; 2014; 39(4):871-81. PubMed ID: 24305500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amyloid-β production via cleavage of amyloid-β protein precursor is modulated by cell density.
    Zhang C; Browne A; Divito JR; Stevenson JA; Romano D; Dong Y; Xie Z; Tanzi RE
    J Alzheimers Dis; 2010; 22(2):683-984. PubMed ID: 20847415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abeta42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Abeta42 species.
    Jan A; Adolfsson O; Allaman I; Buccarello AL; Magistretti PJ; Pfeifer A; Muhs A; Lashuel HA
    J Biol Chem; 2011 Mar; 286(10):8585-8596. PubMed ID: 21156804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel monoclonal antibody 3B8 specifically recognizes pyroglutamate-modified amyloid β 3-42 peptide in brain of AD patients and 3xTg-AD transgenic mice.
    Acero G; Garay C; Venegas D; Ortega E; Gevorkian G
    Neurosci Lett; 2020 Apr; 724():134876. PubMed ID: 32114116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amyloid-beta protofibrils differ from amyloid-beta aggregates induced in dilute hexafluoroisopropanol in stability and morphology.
    Nichols MR; Moss MA; Reed DK; Cratic-McDaniel S; Hoh JH; Rosenberry TL
    J Biol Chem; 2005 Jan; 280(4):2471-80. PubMed ID: 15528204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of Alzheimer's amyloid toxicity with a tricyclic pyrone molecule in vitro and in vivo.
    Hong HS; Rana S; Barrigan L; Shi A; Zhang Y; Zhou F; Jin LW; Hua DH
    J Neurochem; 2009 Feb; 108(4):1097-1108. PubMed ID: 19141069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human Brain-Derived Aβ Oligomers Bind to Synapses and Disrupt Synaptic Activity in a Manner That Requires APP.
    Wang Z; Jackson RJ; Hong W; Taylor WM; Corbett GT; Moreno A; Liu W; Li S; Frosch MP; Slutsky I; Young-Pearse TL; Spires-Jones TL; Walsh DM
    J Neurosci; 2017 Dec; 37(49):11947-11966. PubMed ID: 29101243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Brain-Targeting Bispecific-Multivalent Antibody Clears Soluble Amyloid-Beta Aggregates in Alzheimer's Disease Mice.
    Rofo F; Meier SR; Metzendorf NG; Morrison JI; Petrovic A; Syvänen S; Sehlin D; Hultqvist G
    Neurotherapeutics; 2022 Sep; 19(5):1588-1602. PubMed ID: 35939261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A monoclonal antibody against synthetic Aβ dimer assemblies neutralizes brain-derived synaptic plasticity-disrupting Aβ.
    O'Nuallain B; Klyubin I; Mc Donald JM; Foster JS; Welzel A; Barry A; Dykoski RK; Cleary JP; Gebbink MF; Rowan MJ; Walsh DM
    J Neurochem; 2011 Oct; 119(1):189-201. PubMed ID: 21781116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intraperitoneal Administration of Monoclonal Antibody Against Pathologic Aβ42 Aggregates Alleviated Cognitive Deficits and Synaptic Lesions in APP/PS1 Mice.
    Xiao S; Song LL; Li JT; Wang H; Yu N; Wang ZQ; Zhang Y; He JS; Hung T
    J Alzheimers Dis; 2020; 73(2):657-670. PubMed ID: 31839610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid amyloid-β oligomer and protofibril accumulation in traumatic brain injury.
    Abu Hamdeh S; Waara ER; Möller C; Söderberg L; Basun H; Alafuzoff I; Hillered L; Lannfelt L; Ingelsson M; Marklund N
    Brain Pathol; 2018 Jul; 28(4):451-462. PubMed ID: 28557010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantification of Alzheimer amyloid beta peptides ending at residues 40 and 42 by novel ELISA systems.
    Jensen M; Hartmann T; Engvall B; Wang R; Uljon SN; Sennvik K; Näslund J; Muehlhauser F; Nordstedt C; Beyreuther K; Lannfelt L
    Mol Med; 2000 Apr; 6(4):291-302. PubMed ID: 10949910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease.
    Kawarabayashi T; Shoji M; Younkin LH; Wen-Lang L; Dickson DW; Murakami T; Matsubara E; Abe K; Ashe KH; Younkin SG
    J Neurosci; 2004 Apr; 24(15):3801-9. PubMed ID: 15084661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diffusible, highly bioactive oligomers represent a critical minority of soluble Aβ in Alzheimer's disease brain.
    Hong W; Wang Z; Liu W; O'Malley TT; Jin M; Willem M; Haass C; Frosch MP; Walsh DM
    Acta Neuropathol; 2018 Jul; 136(1):19-40. PubMed ID: 29687257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.
    Kawarabayashi T; Younkin LH; Saido TC; Shoji M; Ashe KH; Younkin SG
    J Neurosci; 2001 Jan; 21(2):372-81. PubMed ID: 11160418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic intranasal treatment with an anti-Aβ(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease.
    Cattepoel S; Hanenberg M; Kulic L; Nitsch RM
    PLoS One; 2011 Apr; 6(4):e18296. PubMed ID: 21483675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins.
    Pham E; Crews L; Ubhi K; Hansen L; Adame A; Cartier A; Salmon D; Galasko D; Michael S; Savas JN; Yates JR; Glabe C; Masliah E
    FEBS J; 2010 Jul; 277(14):3051-67. PubMed ID: 20573181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pyroglutamate-modified amyloid-β protein demonstrates similar properties in an Alzheimer's disease familial mutant knock-in mouse and Alzheimer's disease brain.
    Wu G; Miller RA; Connolly B; Marcus J; Renger J; Savage MJ
    Neurodegener Dis; 2014; 14(2):53-66. PubMed ID: 24158021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The aqueous phase of Alzheimer's disease brain contains assemblies built from ∼4 and ∼7 kDa Aβ species.
    Mc Donald JM; O'Malley TT; Liu W; Mably AJ; Brinkmalm G; Portelius E; Wittbold WM; Frosch MP; Walsh DM
    Alzheimers Dement; 2015 Nov; 11(11):1286-305. PubMed ID: 25846299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.